Literature DB >> 1940788

On the nature of peptides involved in T cell alloreactivity.

O Rötzschke1, K Falk, S Faath, H G Rammensee.   

Abstract

The strong reaction of T cells against foreign major histocompatibility complex (MHC) antigens, commonly termed "alloreactivity", is not only a nuisance for clinical organ transplantation; it also remains a puzzling question for immunologists. By making use of recent technical developments, alloreactive T cells nominally directed against a mutation in a single MHC class I molecule were found to fall into several major categories. One is recognizing peptides whose occurrence is dependent on one particular MHC allele, another is recognizing peptides supported by several MHC alleles, and a third is recognizing peptides occurring independently of MHC alleles. In a fourth category, the binding to MHC of any of a broad range of peptides appears sufficient. In addition, there are T cells for which no peptide involvement could be detected at all. Even within these categories, the heterogeneity of T cells is considerable: among 16 Kb-reactive T cells analyzed, 15 different modes of reactions were found.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1940788      PMCID: PMC2118982          DOI: 10.1084/jem.174.5.1059

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  44 in total

1.  Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens?

Authors:  P Matzinger; M J Bevan
Journal:  Cell Immunol       Date:  1977-03-01       Impact factor: 4.868

Review 2.  Fine specificity analysis with monoclonal antibodies of antigens controlled by the major histocompatibility complex and by the Qa/TL region in mice.

Authors:  H Lemke; G J Hämmerling; U Hämmerling
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

3.  Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Nature       Date:  1974-04-19       Impact factor: 49.962

4.  Cytolytic T lymphocyte precursors reactive against mutant Kb alloantigens are as frequent as those reactive against a whole foreign haplotype.

Authors:  M B Widmer; H R MacDonald
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

5.  Target sites for antibodies and cytotoxic T lymphocytes on H-2 molecules.

Authors:  E Rüsch; W Kuon; G J Hämmerling
Journal:  Transplant Proc       Date:  1983-12       Impact factor: 1.066

6.  Recognition of conformational determinants on H-2 by cytolytic T lymphocytes.

Authors:  L A Sherman
Journal:  Nature       Date:  1982-06-10       Impact factor: 49.962

7.  Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors.

Authors:  K F Lindahl; D B Wilson
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

8.  T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules by HLA-DP.

Authors:  H S de Koster; D C Anderson; A Termijtelen
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

9.  Fine specificity of alloimmune cytotoxic T lymphocytes directed against H-2K. A study with Kb mutants.

Authors:  C J Melief; L P de Waal; M Y van der Meulen; R W Melvold; H I Kohn
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

10.  Role of the H-2 complex in the induction of T cell tolerance to self minor histocompatibility antigens.

Authors:  E S Groves; A Singer
Journal:  J Exp Med       Date:  1983-11-01       Impact factor: 14.307

View more
  41 in total

Review 1.  Immune recognition, response, and regulation: how T lymphocytes do it.

Authors:  S Joyce
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex.

Authors:  M H Heemskerk; R A de Paus; E G Lurvink; F Koning; A Mulder; R Willemze; J J van Rood; J H Falkenburg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

3.  Development of organised conjunctival leucocyte aggregates after corneal transplantation in rats.

Authors:  S Banerjee; F C Figueiredo; D L Easty; A D Dick; S M Nicholls
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

4.  Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells.

Authors:  E Z Wolpert; M Petersson; B J Chambers; J K Sandberg; R Kiessling; H G Ljunggren; K Kärre
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

5.  Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells.

Authors:  R A Henderson; A L Cox; K Sakaguchi; E Appella; J Shabanowitz; D F Hunt; V H Engelhard
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

Review 6.  [Immunologic, alloantigen-dependent factors in chronic graft rejection].

Authors:  C Barth; J Stachowski; A von Menges; P Lammerding; C A Baldamus
Journal:  Med Klin (Munich)       Date:  1998-01-15

7.  A mutation in the alpha 3 domain of Db that abrogates CD8 binding does not affect presentation of an immunodominant H-Y peptide.

Authors:  J P Dutz; S J Teh; N Killeen; H S Teh
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

Review 8.  Allo-reactive T cells for the treatment of hematological malignancies.

Authors:  J H F Falkenburg; I Jedema
Journal:  Mol Oncol       Date:  2015-10-24       Impact factor: 6.603

Review 9.  Heat shock proteins transfer peptides during antigen processing and CTL priming.

Authors:  P K Srivastava; H Udono; N E Blachere; Z Li
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

10.  Human T cells expressing V beta 8 do not predominantly recognize DR2 alloantigen.

Authors:  S E Christmas; R Brew; I Crosby; I E Gecim; R A Sells
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.